跳至主要内容
临床试验/CTRI/2019/06/019516
CTRI/2019/06/019516尚未招募2 期

An open label single arm clinical study to evaluate the safety and efficacy of PR/HC/17-18/003 formulation for weight management in obese or overweight patients. - Nil

Aayush Healthcare0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1 Male and or female patients.
  • 2 Age between 20 to 50 years.
  • 3 BMI between 25 to 40 kg/m2.
  • 4 Willing to come for regular follow-up visits.
  • 5 Able to give written informed consent.

排除标准

  • 1 Intake of over the counter weight loss agents, centrally acting
  • appetite suppressants in the previous six months.
  • 2 Pathophysiologic/ genetic syndromes associated with obesity
  • (Cushingâ??s syndrome, Turnerâ??s syndrome, Praderwilli syndrome).
  • 3 Patients with evidence of malignancy.
  • 4 Patients with poorly controlled Diabetes Mellitus (HbA1c > 10%).
  • 5 Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg).
  • 6 Patients on prolonged ( > 6 weeks) medication with corticosteoids,
  • antidepressants, anticholinergics, etc. or any other drugs that may
  • have an influence on the outcome of the study.
  • 7 Symptomatic patient with clinical evidence of Heart failure.
  • 8 Patients with concurrent serious hepatic disorder (defined as
  • Aspartate Amino
  • Transferase (AST) and / or Alanine Amino Transferase (ALT), Total
  • Bilirubin,Alkaline Phosphatase (ALP) > 2 times upper normal limit) or
  • Renal Disorders (defined as S.Creatinine >1.2mg/dL), Severe
  • Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or
  • Chronic Obstructive Pulmonary Disease [COPD]), or any other
  • condition that may jeopardize the study.
  • 9 History of HIV and other viral infections.
  • 10 Alcoholics and/or drug abusers.
  • 11 Prior surgical therapy for obesity.
  • 12 History of hypersensitivity to any of the herbal extracts or dietary
  • supplement.
  • 13 Pregnant / lactating woman.
  • 14 Patients who have completed participation in any other clinical
  • trial during the past six (06) months.
  • 15 Any other condition which the Principal Investigator thinks may
  • jeopardize the study

研究者

相似试验